Investigation of response factors for monotherapy with immune checkpoint inhibitors in non‐small cell lung cancer patients with PD‐L1 expression <50%

BACKGROUND: Immune checkpoint inhibitor (ICI) monotherapy is currently approved for the treatment of advanced non‐small cell lung cancer (NSCLC) patients with programmed death ligand‐1 (PD‐L1) expression ≥50%. However, the efficacy of ICI monotherapy in patients with PD‐L1 expression <50% has not...

Descripción completa

Detalles Bibliográficos
Autores principales: Takahara, Yutaka, Abe, Ryudai, Sumito, Nagae, Tanaka, Takuya, Ishige, Yoko, Shionoya, Ikuyo, Yamamura, Kouichi, Nishiki, Kazuaki, Nojiri, Masafumi, Kato, Ryo, Shinomiya, Shohei, Oikawa, Taku
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley & Sons Australia, Ltd 2023
Materias:
Original Articles
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10518233/
https://www.ncbi.nlm.nih.gov/pubmed/37536667
http://dx.doi.org/10.1111/1759-7714.15059

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10518233/
https://www.ncbi.nlm.nih.gov/pubmed/37536667
http://dx.doi.org/10.1111/1759-7714.15059

Ejemplares similares